tucatinib,trastuzumab
seagen
data of mountaineer: global, open-label, phase 2 trial: trastuzumab+tucatinib presented by john h. strickler
at 2022 
MD-PhD
Passionate Oncologist
Focus on Molecular Oncology 
Focus on Gastrointestinal Oncology